Degron Therapeutics vs Sable Bio
Degron Therapeutics vs Sable Bio, compared side by side on 14 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Degron Therapeutics is on 62/100 and Sable Bio on 41/100.
Where each one leads
Degron Therapeutics
- our overall score: 62/100 against 41/100
- domain rating: 25/100 against 15/100
- funding raised: $40.0M against $3.1M
Sable Bio
- agent readiness: 44/100 against 27/100
At a glance
| Measure | Degron Therapeutics | Sable Bio |
|---|---|---|
| What it is | Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines. | AI drug safety startup |
| Category | Biotechnology, Pharmaceuticals, Drug Discovery, Healthcare | Biotechnology, Artificial Intelligence, Drug Discovery, Pharmaceuticals |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Platform |
| Founded | 2020 | 2022 |
| Headquarters | San Diego, USA | London, United Kingdom |
| Status | Active | Active |
Size, funding and growth
| Measure | Degron Therapeutics | Sable Bio |
|---|---|---|
| Employees | 24 | Not published |
| Total funding | $40.0M | $3.1M |
| Latest round | Series A Extension | Unknown |
| Valuation | $1.1B | $1.1B |
| LinkedIn followers | 1,380 | Not published |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Degron Therapeutics | Sable Bio |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 62/100 | 41/100 |
| Traction | Not published | 32/100 |
| Team | 24/100 | Not published |
| Search visibility | 57/100 | 11/100 |
| Quality | Not published | 58/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (27/100) | D (44/100) |
| Domain ratingLink authority, 0-100 | 25/100 | 15/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Degron Therapeutics | Sable Bio |
|---|---|---|
| Hosting | Self Managed | Not detected |
| CMS | Not detected | Framer |
| Analytics | Not detected | Google Analytics 4 |
Degron Therapeutics vs Sable Bio: common questions
Which is better, Degron Therapeutics or Sable Bio?
On our 0-100 score Degron Therapeutics rates higher (62/100 against 41/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 14 data points above: read the rows that match what you are buying for.
How do Degron Therapeutics and Sable Bio compare on the numbers?
Degron Therapeutics leads on our overall score (62/100 against 41/100), domain rating (25/100 against 15/100), funding raised ($40.0M against $3.1M). Sable Bio leads on agent readiness (44/100 against 27/100).
Read the full Degron Therapeutics review and pricing or the Sable Bio review and pricing. You can also browse other Degron Therapeutics alternatives we track.